Development of a patient-reported outcomes instrument for the measurement of the sexual impacts of psoriasis - 09/05/15
Doi : 10.1016/j.jaad.2015.02.928
Le texte complet de cet article est disponible en PDF.
Jennifer C. Cather, Modern Dermatology, a Baylor Health Texas Affiliate, Dallas, TX, United States; Elizabeth J. Horn, Modern Research Associates, Dallas, TX, United States; Murali Sundaram, AbbVie Inc, North Chicago, IL, United States; Catherine Foley, Adelphi Values, Boston, MA, United States; Ramon Iovin, Adelphi Values, Boston, MA, United States; Farrah Pompilus, Adelphi Values, Boston, MA, United States; Jonathan Stokes, Adelphi Values, Boston, MA, United States; Alan Shields, Adelphi Values, Boston, MA, United States
Le texte complet de cet article est disponible en PDF.| Design, study conduct, and financial support for the study were provided by AbbVie; AbbVie participated in the interpretation of data, review, and approval of the abstract. |
© 2015
Publié par Elsevier Masson SAS.
Vol 72 - N° 5S1
P. AB229 - mai 2015 Retour au numéro
Article précédent
- Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis
- Development of severe psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab: A paradoxical side effect
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?